Phase Ib/II trial in HPV-positive head and neck squamous cell carcinoma. Cohort 1 received vaccine pre and post surgery. Cohort 2 received vaccine after chemoradiation.Results: INO-3112 can safely general HPV-specific CD8 T-cell immunity. This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.